{"DataElement":{"publicId":"5105879","version":"2","preferredName":"Laboratory Procedure Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Code Indicator","preferredDefinition":"The coded indicator related to criteria to determine eligibility of patients for medical care programs and services for any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting of measurement of serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase or alkaline phosphatase present in a sample.","longName":"LAB_AST_ALT_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3257654","version":"1","preferredName":"Laboratory Procedure Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination","preferredDefinition":"information related to criteria to determine eligibility of patients for medical care programs and services for any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting of measurement of serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase or alkaline phosphatase present in a sample.","longName":"2543047v1.0:3257652v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3257652","version":"1","preferredName":"Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination","preferredDefinition":"A quantitative measurement of alkaline phosphatase present in a sample.:Activity measured as a test of liver function, 46/47-kDa homodimeric human Aspartate Aminotransferases (Class-I Pyridoxal-Phosphate-Dependent Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. (NCI):Activity measured as a test of liver function, human Glutamic-Pyruvate Transaminases (Alanine Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Glutamic Pyruvic Transaminases mediate conversion of major intermediate metabolites, catalyzing reversible transamination between alanine and alpha-ketoglutarate to form pyruvate and glutamate. (NCI):Criteria to determine eligibility of patients for medical care programs and services.","longName":"C64432:C25202:C25293:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alkaline Phosphatase Measurement","conceptCode":"C64432","definition":"A quantitative measurement of alkaline phosphatase present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Aspartate Aminotransferase","conceptCode":"C25202","definition":"A family of pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. Aspartate aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-aspartate to alpha-ketoglutarate forming oxaloacetate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Alanine Aminotransferase","conceptCode":"C25293","definition":"A family of pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Alanine aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-alanine to alpha-ketoglutarate forming pyruvate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8FD5CDF-1741-4835-E040-BB89AD43041C","latestVersionIndicator":"Yes","beginDate":"2011-07-26","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-07-26","modifiedBy":"ONEDATA","dateModified":"2011-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8FD5CDF-1752-4835-E040-BB89AD43041C","latestVersionIndicator":"Yes","beginDate":"2011-07-26","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876425","version":"1","longName":"Laboratory Data (including serologic/viral status)","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Are pre-study AST and ALT les","type":"Preferred Question Text","description":"Are pre-study AST and ALT less than 2.5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Is screening visit alkaline phosphatase less than or equal to 2.5 x ULN (less than or equal to 5 x ULN for patients with documented liver involvement or bone metastases)?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x ULN (less than or equal to 5 x ULN for patients with documented liver involvement or bone metastases)?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional upper limit of normal for age?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.0 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Are pre-study AST (SGOT) and ALT (SGPT) less than or equal to 3 x ULN OR less than or equal to 5 x ULN for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Are pre study AST and ALT less than 10 x upper limit of normal, as assessed by treating investigator?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Is pre-study ALT (SGPT) less than or equal to 135 U/L (i.e., 3 x ULN)?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 3 x institutional upper limit of normal (ULN)?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional ULN (less than or equal to 5 x ULN for subjects with liver metastasis), within 14 days prior to treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Is pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional ULN (or less than or equal to 5 x upper limit of reference range if considered to be related to liver or bone metastases by the PI)?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 5 x institutional ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Are pre-study AST (SGOT) and ALT (SGPT) less than or equal to 3 x the upper limit of normal OR less than or equal to 5 x the upper limit of normal for patients with liver metastases, within 3  days prior to the first day of 7+3?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional ULN / 2 x institutional upper limit of normal, respectively?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 3 x institutional upper limit of normal or 5 x the institutional upper limit of normal if liver metastasis is present within 14 days of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Are pre-study AST(SGOT) and ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal (SGOT less than or equal to 39 U/L and SGPT less than or equal to 52 U/L)?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x institutional upper limit of normal (less than or equal to 5 x ULN for patients with documented liver or bone metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 3 x institutional upper limit of normal (ULN), unless due to Gilbert's disease, hemolysis, or lymphomatous involvement of liver?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional ULN (less than or equal to 5 x ULN for subjects with liver metastasis), within 14 days prior to treatment?","url":null,"context":"Theradex"},{"name":"Theradex - Corrected 20","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional ULN (less than or equal to 5 x ULN for subjects with liver metastasis), within 14 days prior to treatment?","url":null,"context":"Theradex"},{"name":"Theradex- 21","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 3 x institutional upper limit of normal (ULN), unless due to Gilbert's disease, hemolysis, or lymphomatous involvement of liver, in which case AST(SGOT)/ALT(SGPT) should be less than or equal to 5 x institutional ULN?","url":null,"context":"Theradex"},{"name":"Alliance 1","type":"Alternate Question Text","description":"Is AST or ALT > 3 x ULN clearly attributable to liver metastases?","url":null,"context":"Alliance"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Are pre-study AST (SGOT) and ALT (SGPT) less than or equal to 3 times the institutional ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 3 X institutional upper limit of normal (ULN) or less than or equal to 5.0 x institutional ULN for participants with documented liver metastases?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B3E9395-6C07-4718-E053-F662850AE613","latestVersionIndicator":"Yes","beginDate":"2016-01-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-01-03","modifiedBy":"SOKKERL","dateModified":"2024-02-13","changeDescription":"Curated for CITN-12. bsm Version to 2.0 , different VD attached 1/3/20 ls","administrativeNotes":"7/28/2022: fixed the symbol x in AQTs.wz","unresolvedIssues":null,"deletedIndicator":"No"}}